Merck & Co (MRK)
76.46
+0.00 (0.00%)
NYSE · Last Trade: Apr 17th, 6:28 AM EDT
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Via StockStory · April 17, 2025
Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology.
Via Benzinga · April 15, 2025
Rep. Marjorie Taylor Greene (R-Ga.) disclosed her significant stock purchases made just before and on the day of former President Donald Trump's announcement to pause global tariffs. This announcement had a substantial impact on the stock market.
Via Benzinga · April 15, 2025
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
Via Benzinga · April 11, 2025
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.
Via Investor's Business Daily · April 10, 2025
These robotics companies could find an opportunity if the latest round of tariffs stimulates an increase in U.S. manufacturing capacity.
Via MarketBeat · April 10, 2025
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Via Benzinga · April 9, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via Chartmill · April 9, 2025
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Via Investor's Business Daily · April 9, 2025
President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.
Via Benzinga · April 9, 2025
Via The Motley Fool · April 9, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.
Via StockStory · April 8, 2025
Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major sectors.
Via Benzinga · April 7, 2025
Uncovering Dividend Opportunities with MERCK & CO. INC. (NYSE:MRK).
Via Chartmill · April 7, 2025

The past six months haven’t been great for Merck. It just made a new 52-week low of $79.69, and shareholders have lost 26.6% of their capital. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Via StockStory · April 7, 2025
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Via Benzinga · April 4, 2025
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.
Via Benzinga · April 3, 2025
It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad.
Via Investor's Business Daily · April 2, 2025
MERCK & CO. INC. has a stellar value proposition. NYSE:MRK not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
Via Chartmill · April 2, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.
Via Chartmill · April 1, 2025
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles.
Via Investor's Business Daily · April 1, 2025